DNA Aptamer against Acute Myeloid Leukemia (AML) Cancer Cells

DNA Aptamer against Acute Myeloid Leukemia (AML) Cancer Cells

$249.00$629.00

DNA Aptamers against Acute Myeloid Leukemia (AML) Cancer Cells

SKU: APT-072 Category:

Background

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. AML cell lines are used in research to study the biology of AML and to develop new treatments. Some commonly used AML cell lines:

  • HL-60: A human promyelocytic leukemia cell line.
  • KASUMI-1: A cell line with a t(8;21) translocation.
  • THP-1: A human monocytic leukemia cell line.
  • OCI-AML3: A cell line with an inv(16) mutation.
  • MV4-11: A human myelomonocytic leukemia cell line.

These cell lines are valuable for understanding the molecular mechanisms of AML and for testing potential therapeutic agents.

Fusion BioLabs provides validated DNA aptamer against those acute myeloid leukemia cancer cells.

 

Product Specification

Aptamer type: DNA aptamer

Aptamer length: 59 bp

Affinity KD: 101 nM by Cell-SELEX

Storage: keep at -20°C. DNA aptamers are guaranteed stable for 12 months when properly stored.

Weight 0.5 lbs
Dimensions 1 × 1 × 1 in
Size

10 nmol, 30 nmol

DOCUMENTATION

Data Sheet

Aptamer Development Services

Nucleic Acid AptamersFind Better Aptamers using Structured Aptamer LibrariesLearn More
Magnetic beads-based SELEXFind DNA/RNA Aptamers against Targets Immobilized on Magnetic BeadsLearn More
Capture-SELEXFind DNA/RNA Aptamers Using Immobilized Aptamer LibraryLearn More
Cell-SELEXIdentify either Cell-Surfaced or Cell-Internalized DNA/RNA Aptamers Learn More
Peptide AptamersIdentify Peptide Aptamers Using Beads-Based Phage Panning PlatformLearn More
Aptamer-based Biomarker DiscoveryDiscover Biomarkers Using Aptamer-Facilitated PlatformsLearn More